Evidence map›Paper›PMID 34179697›Full record

ArticleHemaSphere2021

Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group.

Carsten Hirt, Eva Hoster, Michael Unterhalt, Mathias Hänel, Gabriele Prange-Krex, Roswitha Forstpointner, Axel Florschütz, Ullrich Graeven, Norbert Frickhofen, Gerald Wulf and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 15 institutions in 1 country.

Carsten HirtKlinik für Innere Medizin C, Universitätsmedizin Greifswald, Germany.
Eva HosterMedizinische Klinik III, Klinikum der Universität München, Germany.
Michael UnterhaltMedizinische Klinik III, Klinikum der Universität München, Germany.
Mathias HänelKlinik für Innere Medizin III, Klinikum Chemnitz, Germany.
Gabriele Prange-KrexGemeinschaftspraxis Innere Medizin, Hämatologie, Onkologie, Dresden, Germany.
Roswitha ForstpointnerMedizinische Klinik III, Klinikum der Universität München, Germany.
Axel FlorschützKlinik für Innere Medizin, Städtisches Klinikum Dessau, Germany.
Ullrich GraevenKlinik für Hämatologie, Onkologie und Gastroenterologie, Kliniken Maria Hilf, Mönchengladbach, Germany.
Norbert FrickhofenMedizinische Klinik III, Dr.-H.-Schmidt-Kliniken Wiesbaden, Germany.
Gerald WulfInnere Medizin-Hämatologie/Onkologie, Georg-August-Universität Göttingen, Germany.
Eva LengfelderIII. Medizinische Klinik, Klinikum Mannheim, Germany.
Christian LerchenmüllerHämato-Onkologische Gemeinschaftspraxis, Münster, Germany.
Rudolf SchlagHämatologisch-Onkologische Schwerpunktpraxis, Würzburg, Germany.
Judith DierlammMedizinische Klinik II, Universitätsklinikum Eppendorf, Hamburg, Germany.
Ludwig Fischer von WeikersthalHämatologie/Onkologie, Gesundheitszentrum St. Marien, Amberg, Germany.
Asima AhmedMedizinische Klinik III, Städtisches Klinikum Braunschweig, Germany.
Hanns-Detlev HarichOnkologische Schwerpunktpraxis Hof, Germany.
Andreas RosenwaldInstitut für Pathologie, Universität Würzburg, Germany.
Wolfram KlapperInstitut für Hämatopathologie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.
Martin DreylingMedizinische Klinik III, Klinikum der Universität München, Germany.
Wolfgang HiddemannMedizinische Klinik III, Klinikum der Universität München, Germany.
Michael HeroldHelios Klinikum Erfurt, Germany.
LMU Klinikum · DEPraxis für Hämatologie und Onkologie · DEHelios Dr. Horst Schmidt Kliniken Wiesbaden · DEHelios Klinikum Erfurt · DEKliniken Maria Hilf · DEKlinikum Braunschweig · DEKlinikum Chemnitz · DEKlinikum St. Marien Amberg · DEStädtisches Klinikum Dessau · DEUniversitätsmedizin Greifswald · DEUniversity Hospital Schleswig-Holstein · DEUniversity Medical Center Hamburg-Eppendorf · DEUniversity Medical Centre Mannheim · DEUniversity of Göttingen · DEUniversity of Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The German study groups, the German Low-Grade Lymphoma Study Group (GLSG) and Ostdeutsche Studiengruppe Hämatologie und Onkologie (OSHO), initiated in 2007 a double randomized trial to investigate efficacy and safety of rituximab maintenance versus observation in remission after randomly assigned induction treatment in the first-line follicular lymphoma. Previously untreated patients with stage II-IV follicular lymphoma in need of therapy were randomized to receive 6 cycles of R-CHOP, R-MCP, or R-FCM. Responding patients were subsequently randomized to 2 years rituximab maintenance or observation, stratified by type of immunochemotherapy, quality of remission, and Follicular Lymphoma International Prognostic Index (FLIPI). Recruitment was stopped in 2011 after the PRIMA results had been published. Median age of the 206 recruited patients was 66 years (range, 24-86), and (FLIPI) was low in 13%, intermediate in 28%, and high in 60%. High and comparable overall response rates were observed after R-CHOP (88%), R-MCP (89%), and R-FCM (91%). Rituximab maintenance substantially prolonged progression-free survival (PFS) in comparison to observation in remission (hazard ratio 0.39,

Identifiers

PMID34179697
PMCPMC8221804
OpenAlexW3173310893

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.